PelliScope

AI-Powered Dermatological Decision Support

01 | The Product

Clinically-Validated AI
For Any Workflow

Ready to Deploy For

Pre-Medical Inquiry

Triage before the patient sees a doctor
Tele-Medicine Consultation

Cost-effective remote patient consultation
In-Patient Appointment Schedule

Prioritize urgency while sharing interim home care guidance

Patient Scan: #8829-A

ANALYSIS COMPLETE

Primary Detection

Herpes Zoster

74%

Confidence

Allergic Dermatitis59%

80.2% Accuracy on Technical Validation

Core Capabilities

Instant Clinical Support

Instantly distinguishes between infectious vs. non-infectious lesions to protect staff.

Diagnostic Assessment

Probability scoring for 10 common conditions (Eczema, Psoriasis, Tinea, etc.).

CPU-Optimized

Resource optimized for any hardware. On-premises deployable—data never leaves your control.

Operational Impact

Workflow Efficiency & Unit Economics

02 | Pre-Consultation Efficiency for Tele-Medicine

Workflow Comparison

+10 Patients / 5hr Shift

Traditional (No AI) 10 Min / Patient

Consultation (10m)

6 Patients / Hour

With PelliScope ~10 Min Total (Parallelized)

Preliminary
Diagnosis (3m)

Focused
Consult (7m)

AI triage saves 3 mins of discovery time per patient

8 Patients / Hour

Model Performance (AUC)

Zero-shot comparison on dermatology benchmarks

Grok-4

0.70

GPT-5

0.81

Gemini 2.5

0.82

PelliScope

0.86

Technical Accuracy: 80.2% Infectious vs Non-infectious flag

10-condition panel

Eczema, Allergic Contact Dermatitis, Insect Bite, Urticaria, Psoriasis, Folliculitis, Irritant Contact Dermatitis, Tinea, Herpes Zoster, Drug Rash.

Unit Economics (Daily)

Infrastructure Cost

$2.50

Daily Compute Spend (6 Hours)

Machine Specs

8 Core CPU

16 GB RAM

CPU Edge Inference

"A single machine costing less than a cup of coffee per day drives this entire workflow."

Clinical Revenue Gain

US & UAE Ready

$800+

Daily Additional Revenue

10+ Add. Patients

@ $80 avg. consult fee

Commercial Models

API call's based liscengin

$4k

Liscince 4k dollars per instance, including $0.5 per Query.

Self-screening inquiries at scale

On-prem deployment

$15k

Includes telemedicine UI; $15k per instance (per-query cost separate).

• Hospital Deployments ($15k/user)
• Self-screening inquiries at scale
• White-label for private networks

Investment Opportunity

Strategic Market Entry

03 | Technology Showcase & GCC Partner

Status: Active Engagement Dubai, UAE

Federal Healthcare Integration

We are in advanced discussions with the Emirates Health Services (EHS) to integrate PelliScope into the federal clinical pipeline. The solution is shortlisted for a PoC to validate efficacy across EHS facilities.

Shortlisted for PoC

Invited to WHX & Arab Health 2026

Document

Official Letter of
Acknowledgement

From Emirates Health Services

Total Addressable Market

$1.9 Billion

2024 Global AI Dermatology Valuation

Projected $6–8B market by 2035

Current focus: GCC + US + UK hospital systems

Growth Rate

33% CAGR

Projected growth 2025–2035

Demand driven by tele-derm adoption + onsite triage

Arab Health 2026 showcase anchors GCC entry

Deployment Roadmap

Proof of Concept (Current)

Shortlisted by EHS Evaluation Committee
WHX & Arab Health 2026

Official Tech Showcase at EHS Booth
Full Integration

Clinical Pipeline Deployment

Investment Opportunity

Strategic Market Entry

04 | Funding Agenda

HawkFranklin Research is bootstrapped and ready to scale. We are launching a new Dubai-based entity to service GCC partnerships and are seeking capital for two distinct goals:

Urgent Funding

Deployment & Marketing

$15k to 50k

Establish hospital and clinic networks across US, UK & GCC
Cover logistics support for conferences
Available as Convertible Note
Application deploy in multiple markets

Scale 2

Multi-disease & Geo Scale

$250k

Pre-cancerous skin lesion pathways
Proprietary dataset expansion: SE Asia & Europe
International data collection teams
Team scale & new-condition validation

Projected ARR (18 Mo)

$1.2 Million

Early Investor Potential

4x ROI

Future Directions

• Expand to rare and pre-cancerous lesions with dermoscopy
• Pair longitudinal EHR + imaging for chronic monitoring
• Add clinician-in-the-loop labeling to speed new markets

Current Rollout Plan

• Clinical deployment in UAE by Oct 2025
• Expansion into India & SE Asia by Sep 2026
• EU data partnership & rollout prep by Dec 2026
• GCC-wide rollout by March 2027

Get In Touch

Email Us

invest@hawkfranklin.in

HawkFranklin Research is a deep-tech company specializing in clinical AI solutions.

Leadership

The PelliScope Team

05 | PelliScope Team

Vatsal Patel

Founder & Research Engineer

M.Sc Artificial Intelligence (IU Berlin)

Dr. Abhijeet Patel

Clinical Research Physician

Bachelor of Medicine & Surgery

Dr. Yash Patel

Clinical Research Physician

Bachelor of Medicine & Surgery

Dr. Nishi Seth

Consultant Dermatologist

M.D Dermatology

Saurav Roy

Operations Head

M.Tech Biotechnology

Ananya Pal

Finance & Accounting Head

B.S Economics

Vision & Portfolio

How HawkFranklin Operates

Operational Revenue Model

Path A: HFR-Initiated Products

We identify a market gap, build a validated product (like PelliScope), and then seek commercial partners to scale it.

Path B: Partner-Initiated R&D

You bring a defined challenge. We build the dedicated AI solution, acting as your external deep-tech R&D team.

Our Philosophy

HawkFranklin’s long-term vision is to innovate science with commercial rigor. Our team spans physicists, chemists, biologists, and AI engineers who are building breakthroughs across quantum computing, finance, and healthcare.

"We are a resilient, self-funded team. We will succeed with or without external funding—this is an opportunity to join a team that is already moving forward."

Broader Biomedical Portfolio

OncoGemma

AI agents for digital pathology analysis

C-Risq

Multi-omics for cancer risk stratification

MedDiscover

RAG copilot for biomedical Q&A

Clinical FM

Foundation models for tabular EHR data

Beyond PelliScope, we maintain specialist pods across these domains to spin up commercialization-ready products wherever the science demands it.